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Introduction
Stent thrombosis is a rare but fatal complication of drug eluting 
stent (DES). Although dual antiplatelet therapy with aspirin and 
clopidogrel significantly reduced the occurrence of stent thrombo-
sis, late stent thrombosis still occurs; many other factors could be 
attributable to the occurrence.1)2) Of these, clopidogrel resistance is 
regarded as one of the main reasons for the occurrence of DES th-
rombosis. Therefore, new antiplatelet agents have been developed 
recently and are reported to have better outcomes.3) We report a 
case of recurrent DES thrombosis with clopidogrel resistance suc-
cessfully rescued by prasugrel. 
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Stent thrombosis is a very serious problem after drug-eluting stent (DES) implantation even though its incidence is about or less than 1%. 
As the clopidogrel resistance is expected to play an important role in the occurrence of stent thrombosis, new anti-platelet agents over-
coming this issue can give us another choice. We experienced a case of a 58-year-old male with successful prasugrel rescue therapy in a pa-
tient with clopidogrel resistance who had recurrent stent thrombosis following DES implantation. (Korean Circ J 2013;43:343-346)
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Case
A 58-year-old non-smoker male who had no specific medical his-
tory visited the emergency room with typical angina on April 2006. 
Coronary angiographic findings showed significant narrowing at 3 
major epicardial arteries (Fig. 1A and B). Percutaneous coronary in-
tervention with 3.0×23 mm-sized sirolimus-eluting stent (CYPHER®; 
Cordis Corp., Miami Lakes, FL, USA) at the mid portion of the left an-
terior descending artery (m-LAD) and 2.75×18 mm-sized sirolimus-
eluting stent at the distal portion of left circumflex artery (d-LCx) 
were performed (Fig. 1C). He received triple antiplatelet drugs (aspi-
rin 100 mg daily, clopidogrel 75 mg daily, cilostazol 100 mg twice dai-
ly). After that, cilostazol and clopidogrel were discontinued on July 
2006 (3-month use) and on June 2009 (37-month use), respective-
ly. Three weeks after clopidogrel discontinuation, he felt typical an-
gina and was diagnosed with non-ST-segment-elevated myocardi-
al infarction (creatine kinase-MB 5.64 ng/mL, Troponin-T 0.019 ng/
mL). On the coronary angiography, intraluminal thrombi in the distal 
portion of m-LAD stent and totally occluded d-LCx stent were noted 
(Fig. 1D, E and F). Percutaneous coronary intervention with 3.0×20 
mm-sized balloon was performed on m-LAD and d-LCx stents as well 
as on the distal portion of LAD. Thereafter, triple antiplatelet therapy, 
including cilostazol 100 mg twice daily, was restarted. The patient 
had no further chest pain and cilostazol and clopidogrel were discon-
tinued on March 2010 (9-month use) and on June 2010 (12-month 
use), respectively.
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However, he visited the emergency room again on Jan 2011 be-
cause of a severe ongoing chest pain. Electrocardiogram showed ST 
elevation (>1 mm) on the anterior (V 1-3) lead. Emergency coronary 
angiography was performed and both m-LAD and d-LCx stents 
were totally obstructed on the angiogram (Fig. 2A and B). Throm-
bus aspiration (Thrombuster II; Kaneka Medix Corporation, Osaka, 
Japan) and balloon dilation with 3.0×15 mm-sized balloon were 
performed on both m-LAD and d-LCx stents (Fig. 2C). Because of the 
drop of blood pressure during the procedure (80/50 mm Hg), intra-
aortic balloon pump (AutoCAT2 WAVE-Fiber Optic; Arrow Interna-
tional Inc., Reading, PA, USA) and percutaneous cardiopulmonary 
support (CAPIOX EBS; Terumo Corporation, Tokyo, Japan) were ap-
plied. Transthoracic echocardiogram was performed right after the 
procedures showed a reduced left ventricular ejection fraction of 
25% with anterior and anteroseptal wall akinesis. Triple antiplate-
let therapy was conducted again. After that, the patient was stable 
and all the other devices were removed; he was sent to the general 
ward. However, thirteen days post procedure, he experienced a se-
vere resting pain again. The resting electrocardiogram showed a ST 
segment elevation on V 1-6 leads. On the emergency angiogram, 
previously treated LAD and LCx stents were occluded again (Fig. 2D 
and E). 
Percutaneous coronary intervention with 3.0×13 mm-sized bal-
loon was performed on m-LAD and d-LCx stents (Fig. 2F). Due to 
suboptimal revascularization flows, 3.0×30 mm-sized zotarolimus-
eluting stent implantation (Endeavor® Sprint; Medtronic Cardio-
Vascular, Minneapolis, MS, USA) was performed on m-LAD. The day 
before the last event, the platelet function test with VerifyNow-
P2Y12® rapid analyzer (Accumetrics Inc., San Diego, CA, USA) sh-
owed inadequate platelet inhibition results {280 P2Y12-receptor Re-
action Units (PRU), 14% inhibition}. 
Finally, clopidogrel was switched with prasugrel 10 mg daily fol-
lowed by a 60 mg loading. Six days later, the platelet function test 
showed an adequate platelet inhibition (9 PRU, 98% inhibition). Af-
ter discharge, cilostazol was discontinued on May 2011 (4-month 
use) and the platelet function test still showed a good response to 
the dual antiplatelet with aspirin and prasugrel (92 PRU, 70% inhi-







Fig. 1. At the first admission, left coronary artery angiography showed tubular eccentric 80% luminal narrowing of the mid portion of the left anterior de-
scending artery (m-LAD) (black arrow) and tubular eccentric 90% luminal narrowing of the distal portion of left circumflex artery (d-LCx) (white arrow) (A and 
B). Successful percutaneous coronary intervention with stent insertion was performed on m-LAD and d-LCx (C). At the second admission, thrombi was observed 
in distal portion of m-LAD stent (black arrow). Also, totally occluded d-LAD lesion (narrow white arrow) and d-LCx stent (white arrow) were noted (D, E and F).
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owed a patent both in LAD and LCx stents. Currently, dual antipla-
telet drugs with aspirin and prasugrel were maintained without any 
chest pain (13-month use) (Fig. 3).
Discussion







Fig. 2. At the third admission, both mid portion of the left anterior descending artery (m-LAD) (black arrow) and distal portion of left circumflex artery (d-
LCx) (white arrow) stents were totally obstructed with thrombi (A and B). After the procedure, revascularization flow was recovered at both stent areas (C). 
In re-stent thrombosis event at the third admission, there were no flows at both stent areas in the emergency angiography (D and E). After balloon dilation 
on m-LAD and d-LCx stents, suboptimal revascularization flows were observed at both stents (F).
Fig. 3. The nine-month follow-up coronary angiography with prasugrel showed good patency of previous stent at mid portion of the left anterior de-
scending artery (black arrow) and distal portion of left circumflex artery (white arrow) lesion without thrombus.
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is the standard medication in patients with DES implantation, the 
unmet needs still exist and fatal complication occurs. Particularly, 
clopidogrel resistance, regarded as one of the major factors for stent 
thrombosis, has been reported to occur in 30-40% of patients.4-7) To 
overcome clopidogrel resistance, a dose-up of clopidogrel or triple 
antiplatelet therapy with cilostazol has been recommended. How-
ever, recent clinical trials, such as GRAVITAS (Gauging Responsive-
ness with A VerifyNow assay-Impact on Thrombosis And Safety) did 
not show a better prognosis than the existing standard-dose dual 
antiplatelet.8) Although some clinical trial described that triple anti-
platelet therapy including cilostazol has a beneficial effect on isch-
emic complications, there are still many debates.9)10) Under this situ-
ation, new anti-platelet agents give us a new choice. Of these, pra-
sugrel, which is hydrolysed by esterases into an intermediate pre-
cursor and whose activation is not involved with oxidation by the 
enzyme CYP2C19,11) can consistently and rapidly inhibit ADP-in-
duced platelet aggregation than clopidogrel.12) Prasugrel was signi-
ficantly superior to clopidogrel for the reduction of ischemic events, 
including stent thrombosis in TRITON-TIMI 38 (TRial to Assess Impro-
vement in Therapeutic Outcomes by Optimizing Platelet InhibitioN 
with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.3) 
Also, some studies reported that prasugrel achieved greater inhibi-
tion of platelet aggregation in clopidogrel resistance patients.13)
Our case revealed the recurrent stent thrombosis events despite 
dual or triple antiplatelet therapy including cilostazol. Many factors 
might be attributable to the occurrence of stent thrombosis. In par-
ticular, new stent implantation (Endeavor® Sprint) at m-LAD could 
make a beneficial contribution for stent thrombosis through the he-
modynamic improvement in the present case. However, d-LCx stent 
(CYPHER®) with balloon-only angioplasty has also shown a good 
patency in a follow-up angiography. Thus, rescued clopidogrel resis-
tance could be the main reason rather than the hemodynamic im-
provement. After the change of antiplatelet into prasugrel, clopido-
grel resistance was successfully rescued and no thrombotic event 
has been observed until now. In conclusion, for the prevention of re-
current DES thrombosis, dual antiplatelet with aspirin and prasugrel 
could be one of the potential options in patients with clopidogrel 
resistance.
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